Scientific conclusions and grounds for the variation to the terms of the marketing authorisations
Taking into account the PRAC Assessment Report on the PSUR(s) for empagliflozin, empagliflozin / metformin, the scientific conclusions of CHMP are as follows: A cumulative review was submitted with this PSUR regarding the important potential risk “Renal impairment”.
Click on this link for more information.
